中国智能健康二零二三年报

Corporate Information Chairman’s Statement Management Discussion and Analysis Corporate Governance Report Report of the Directors Independent Auditors’Report Consolidated Statement of Profit or Loss and Other Comprehensive Income Consolidated Statement of Financial Position Consolidated Statement of Changes in Equity Consolidated Statement of Cash Flows Notes to the Consolidated Financial Statements76 Corporate Information公司資料 EXECUTIVE DIRECTORS Mr. Lei Hong Wai(Chairman)Mr. Cheung Kwok Wai Elton(Vice Chairman)Mr. Leung AlexMs. Lo Ming WanMr. Tse Chi KeungMr. Yuan Huixia INDEPENDENT NON-EXECUTIVE DIRECTORS Mr. Lai Hok LimMr. Lien Wai HungMr. Wong Tak Chuen AUDIT COMMITTEE Mr. Wong Tak Chuen(Chairman)Mr. Lai Hok LimMr. Lien Wai Hung NOMINATION COMMITTEE Mr. Lei Hong Wai(Chairman)Mr. Lai Hok LimMr. Lien Wai HungMr. Wong Tak Chuen REMUNERATION COMMITTEE Mr. Lai Hok Lim(Chairman)Mr. Lei Hong WaiMr. Lien Wai HungMr. Wong Tak Chuen COMPANY SECRETARYMs. Lo Ming Wan AUDITORS HLB Hodgson Impey Cheng Limited31F., Gloucester Tower, The Landmark11 Pedder St, CentralHong Kong LEGAL ADVISERS ON CAYMAN ISLANDS LAW Maples and Calder Asia Maples and Calder Asia26th Floor, Central Plaza18 Harbour RoadWanchaiHong Kong LEGAL ADVISERS ON HONG KONG LAW Robertsons Solicitors57/F, The Center99 Queen’s Road CentralHong Kong REGISTERED OFFICE P.O. Box 309Ugland HouseGrand CaymanKY1-1104Cayman Islands P.O. Box 309Ugland HouseGrand CaymanKY1-1104Cayman Islands HEAD OFFICE AND PRINCIPAL PLACE OF BUSINESSIN HONG KONG Unit 1209Shun Tak Centre, West Tower168–200 Connaught Road CentralHong KongTel: (852) 2268 8248Fax: (852) 2548 5575Website: www.healthwisehk.com (852) 2268 8248(852) 2548 5575www.healthwisehk.com Corporate Information公司資料 PRINCIPAL SHARE REGISTRAR AND TRANSFER OFFICE Maples Fund Services (Cayman) LimitedP.O. Box 1093Boundary HallCricket SquareGrand CaymanCayman IslandsKY1-1102 Maples Fund Services (Cayman) LimitedP.O. Box 1093Boundary HallCricket SquareGrand CaymanCayman IslandsKY1-1102 HONG KONG BRANCH SHARE REGISTRAR ANDTRANSFER OFFICE Tricor Abacus Limited17/F, Far East Finance Centre16 Harcourt RoadHong Kong LISTING INFORMATION The Stock Exchange of Hong Kong LimitedStock Code: 00348Website: www.healthwisehk.com 00348www.healthwisehk.com On behalf of the board of directors (the“Board”or“Directors”) of ChinaHealthwise Holdings Limited (the“Company”) and its subsidiaries(together the“Group”), I present to you the annual results of theCompany and the Group for the year ended 31 December 2023. CORPORATE INFORMATION (852) 22688248(852) 2548 5575 The principal place of business of the Company in Hong Kong is Unit1209, Shun Tak Centre, West Tower, 168–200 Connaught RoadCentral, Hong Kong and the telephone and facsimile numbers of theCompany are (852) 2268 8248 and (852) 2548 5575. RESULTS The Company hereby announces its annual results for the year ended31 December 2023 (the“Reporting Year”or“FY23”). For the ReportingYear, the Group’s turnover increased by approximately (“approx.”) 3%to approx. HK$146 million, compared with approx. HK$142 millionfor the year ended 31 December 2022 (the“FY22”or“CorrespondingYear”). Gross profit margin for the Reporting Year was approx. 41% comparedto approx. 37% in the Corresponding Year. Overall, loss attributable toowners of the Company was approx. HK$135 million compared withHK$54 million in the Corresponding Year. The Directors do notrecommend the payment of any dividend for the year ended 31December 2023 (FY22: Nil). Chairman’s Statement主席報告 BUSINESS REVIEW (1)(2)(3) During the Reporting Year, revenue increased due to the net effect of (1)the increase in revenue from the investment in financial instrumentsegment from loss of approx. HK$1 million in FY22 to gain of approx.HK$6 million in the Reporting Year; (2) the increase in revenue from theChinese health product segment from approx. HK$128 million in FY22to approx. HK$130 million in the Reporting Year; and (3) the decreasein revenue from the money lending segment from approx. HK$15 millionin FY22 to approx. HK$11 million in the Reporting Year. The Group recorded an increase in loss for the year ended 31December 2023 as compared to the year ended 31 December 2022.The increase in loss was mainly due to an increase in the impairmentloss recognised during the year in respect of loan receivables fromapprox. HK$25 million in FY22 to approx. HK$107 million in FY23. Chinese Health Products Chinese health products business engaged in the sales of Chinese andother pharmaceutical products, health products, ginseng and driedseafood products to wholesaler and retailer. Nam Pei Hong Sum YungDrugs Company Limited, one of our subsidiaries, engages in thebusiness of trading and retail of“Sum Yung”and dried seafoodproducts since 1977 and the brand name of“Nam Pei Hong”is highly recognised in Hong Kong and Southern Mainland China. During the Reporting Year, this segment had contributed revenue ofa